Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

December 16th, 2008

Dose-Dense Chemotherapy Plus Bevacizumab Followed by Nab-Paclitaxel Appears Cardiac Safe in Early-Stage Breast Cancer: Presented at SABCS

Abstract:
A dose-dense anthracycline-based therapy that includes bevacizumab followed by nanoparticle albumin-bound paclitaxel (nab-paclitaxel) appears to avoid serious cardiac toxicity in its role as adjuvant treatment for early-stage breast cancer, researchers reported at the 31st Annual San Antonio Breast Cancer Symposium (SABCS).

Heather McArthur, MD, Memorial Sloan-Kettering Cancer Center, New York, New York and colleagues enrolled 80 women with early-stage breast cancer into a trial in which patients were treated with bevacizumab 10 mg/kg administered intravenously every 2 weeks for 8 cycles, concurrently with doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles, and then nab-paclitaxel 260 mg/m2 every 2 weeks for 4 cycles. After 8 cycles, for the rest of 1 year, bevacizumab was administered at a dose of 15 mg/kg every 3 weeks. Pegfilgrastim was administered on day 2 of each chemotherapy cycle.

Source:
docguide.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Nanomedicine

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Announcements

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Events/Classes

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

Stress-free ALD from Picosun August 28th, 2018

Kavli Lectures: New vision of nanomaterial synthesis and light-fueled space travel August 8th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project